"Frontier Pharma: Hematological Disorders - Iron Regulators and Immune Response Targeted Programs Within Anemias and other Red Blood Cell Disorders Hold Potential to Transform Therapy Area with Significant Unmet Need" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
. .
Description-
' '
– The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three categories- red blood cell disorders, bleeding disorders and immune cell disorders - of which red blood cell disorders are characterized by significant unmet need related to few effective treatment options and poor prognosis. As such, they are the primary focus of the report.
Get Sample Report @ https://www.researchmoz.us/enquiry.php?type=S&repid=1313840
' '
– Historically,
the hematological disorders therapy area has suffered from a lack of
funding for research, which has contributed to the level of unmet
need, although there have been instances in which funding for an
indication has resulted in a strong return on investment. A notable
example is the approval of Soliris in 2007, which is used to treat
the orphan disease paroxysmal nocturnal hemoglobinuria. Soliris is
one of only two marketed treatment options for PNH and is forecast to
generate annual revenue of over $3 billion by the end of 2017, rising
to $5.5 billion in 2023.
– The
report assesses first-in-class innovation in the hematological
disorders pipeline, highlighting key trends in the pipeline, and
emerging treatment classes. There are 92 first-in-class products in
development in this therapy area; which account for 28% of products
in the overall pipeline for which there is a disclosed molecular
target, and act upon 71 unique individual molecular targets.
– These
first-in-class targets in the pipeline are numerous and varied, with
many of them having been shown to be promising in early stage
studies. Immune components are the most common, accounting for a
total of 21 first-in-class developmental programs, closely followed
by DNA regulators. These target categories combined account for the
majority of red blood cell disorder pipeline therapies, although iron
regulator programs alone also appear frequently.
– – Scope
– –
-
With 488 products in active development, the pipeline for
hematological disorders is modestly sized. Does current pipeline
innovation hold the potential to affect the future hematological
disorders market?
- There are 92 first-in-class products in the
hematological disorders pipeline, which act on a novel molecular
target which is not present in an approved product across any
indication the pharmaceutical industry. Which of these hold the
greatest potential to improve future disease treatment with regard to
their molecular target?
- Analysis of the history of strategic
consolidations revealed a modest level of deal activity in recent
years and a large number of first-in-class products not yet involved
in any deals. How do deal frequency and value compare between target
families and molecule types, and which first-in-class programs which
have not yet been involved in a licensing or co-development deal
appear to be particularly promising?
– – Reasons
to buy
– –
-
Understand the current clinical and commercial landscape. This
includes a comprehensive study of disease pathogenesis, diagnosis and
prognosis, and the treatment options available.
- Visualize the
composition of the hematological disorders market in terms of
dominant molecule types and targets, highlighting what the current
unmet needs are and how they can be addressed. This knowledge allows
a competitive understanding of gaps in the current market.
-
Analyze the hematological disorders pipeline and stratify by stage of
development, molecule type and molecular target. There are strong
signs in the pipeline that the industry is seeking novel approaches
to treating hematological disorders to overcome the overwhelming
level of unmet need.
- Assess the therapeutic potential of
first-in-class targets. Using a proprietary matrix, first-in-class
products have been assessed and ranked according to clinical
potential. Promising early-stage targets have been reviewed in
greater detail.
- Identify commercial opportunities in the
hematological disorders deals landscape by analyzing trends in
licensing and co-development deals and analyzing a curated list of
hematological disorder therapies that have not yet been involved in
deals, and may offer potential investment opportunities.
. .
More Clear Details get Table of Contents @ https://www.researchmoz.us/frontier-pharma-hematological-disorders-iron-regulators-and-immune-response-targeted-programs-within-anemias-and-other-red-blood-cell-disorders-hold-potential-to-transform-therapy-area-with-significant-unmet-need-report.html/toc
